Since the onset of the COVID-19 pandemic two years ago, hundreds of studies have examined the efficacy of dozens of drugs and other compounds in treating the disease. While the research is still ongoing, a sizable number of treatments have shown promise. A growing number of them have been authorized by the U.S. government, though virtually all of those approved sport hefty price tags.
"It is so refreshing to see actual journalism again! I studied journalism and understand what it means - to report the facts as closely to the truth as you can manage while understanding the reporter will always have some bias of their own. Yet the facts, even if incomplete, are to be reported truthfully. This is not what we get from most "mainstream" media. They have been controlled by the deep state for decades. Someone cares what the majority of us think about people and events and is spending a LOT of money to influence our thinking. I greatly admire the work and dedication to integrity I see in The Epoch Times. Thank you! You inspire others with your efforts. Right is winning!"
In a perfect world, we'd offer you our journalism for free.
But the hours we spend researching, writing, editing and fact-checking can't be supported by advertising alone. Not when our advertisers are threatened into cancelling their contracts and not when platforms like YouTube refuse to monetize (or even host) our content.
Take a stand for an independent outlet—and a stand against Big Tech censorship. Subscribe to The Epoch Times today.
For a limited time, we're offering our full access digital subscription at $1 for your first 2 months.
Together, we can stand stronger and speak louder.
View offer Limited time only. You can cancel anytime.
The Epoch Times, 229 W 28 St, Fl. 5, New York, NY 10001
You are receiving this email because you recently registered for a free account with The Epoch Times. In the days ahead you will receive compelling letters from our editorial staff, practical guides on how to get the most out of our publication and exclusive offers. Want us to stop emailing you? Manage your email preferences here.